Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 108 stocks hit new 52-week highs.
Expert Ratings for Gilead Sciences
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $81
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $68 to $81.
Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures
Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences (NASDAQ:RCUS) announced an update from the fourth interim analysis of Phase 2 ARC-7 study in patients…
What Does Gilead Sciences’ Debt Look Like?
Over the past three months, shares of Gilead Sciences Inc. (NASDAQ:GILD) rose by 34.80%. Before having a look at the importance of debt, let's look at how much debt Gilead Sciences has.
Gilead And Arcus Biosciences Announce Positive Update On Joint TIGIT Program From Interim Analysis of ARC-7 Study In Non-Small Cell Lung Cancer; Shares Spike Higher
– Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $17,000 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 8.0% on an annualized basis…
This Is What Whales Are Betting On Gilead Sciences
Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Gilead Sciences’ Debt Overview
Shares of Gilead Sciences' Inc. (NASDAQ:GILD) rose by 33.62% in the past three months. Before we understand the importance of debt, let's look at how much debt Gilead Sciences' has.
Jim Simons ‘The Man Who Solved The Market’ Sold 3 Healthcare Dividend Payers, But Upped Stake In This One By 153%
Jim Simons is the founder and hedge fund manager of Renaissance Technologies, which currently has a total portfolio value north of $77 billion, per Stock Circle. This hedge fund uses a quantitative strategy in determining its stock trades.